Inhibrx Biosciences, Inc.2025财年第一财季实现净利润-43.31百万美元，同比增加44.98%

市场透视2025-05-23

5月23日，Inhibrx Biosciences, Inc.（INBX.US）公布财报，公告显示公司2025财年第一财季净利润为-43.31百万美元，同比增加44.98%；其中营业收入为0.00美元，每股基本收益为-2.80美元。从资产负债表来看，Inhibrx Biosciences, Inc.（INBX.US）总负债1.48亿美元，其中短期债务1.97百万美元，资产负债比为1.65，流动比率...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2537232369?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-23 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2537232369","market":"us","top_or_hot":-1,"title":"Inhibrx Biosciences, Inc.2025财年第一财季实现净利润-43.31百万美元，同比增加44.98%","media":"市场透视","content":"<div>\n<p>5月23日，Inhibrx Biosciences, Inc.（INBX.US）公布财报，公告显示公司2025财年第一财季净利润为-43.31百万美元，同比增加44.98%；其中营业收入为0.00美元，每股基本收益为-2.80美元。从资产负债表来看，Inhibrx Biosciences, Inc.（INBX.US）总负债1.48亿美元，其中短期债务1.97百万美元，资产负债比为1.65，流动比率...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523000230a6e914ee&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Inhibrx Biosciences, Inc.2025财年第一财季实现净利润-43.31百万美元，同比增加44.98%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInhibrx Biosciences, Inc.2025财年第一财季实现净利润-43.31百万美元，同比增加44.98%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-23 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523000230a6e914ee&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>5月23日，Inhibrx Biosciences, Inc.（INBX.US）公布财报，公告显示公司2025财年第一财季净利润为-43.31百万美元，同比增加44.98%；其中营业收入为0.00美元，每股基本收益为-2.80美元。从资产负债表来看，Inhibrx Biosciences, Inc.（INBX.US）总负债1.48亿美元，其中短期债务1.97百万美元，资产负债比为1.65，流动比率...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523000230a6e914ee&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INBX","symbol_name":"Inhibrx Biosciences","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523000230a6e914ee&s=b","article_id":"2537232369","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523000230a6e914ee&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2537232369","pubTimestamp":1747929643,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"5月23日，Inhibrx Biosciences, Inc.公布财报，公告显示公司2025财年第一财季净利润为-43.31百万美元，同比增加44.98%；其中营业收入为0.00美元，每股基本收益为-2.80美元。从资产负债表来看，Inhibrx Biosciences, Inc.总负债1.48亿美元，其中短期债务1.97百万美元，资产负债比为1.65，流动比率为0.06。机构评级：截至2025年5月23日，当前有1家机构对Inhibrx Biosciences, Inc.目标价做出预测，其中目标均价为12.00美元，其中最低目标价为12.00美元，最高目标价为12.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"INBX":"Inhibrx Biosciences"},"translate_title":"Inhibrx Biosciences, Inc. achieved net profit of-US $43.31 million in the first fiscal quarter of fiscal year 2025, a year-on-year increase of 44.98%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INBX":1},"content_text":"5月23日，Inhibrx Biosciences, Inc.（INBX.US）公布财报，公告显示公司2025财年第一财季净利润为-43.31百万美元，同比增加44.98%；其中营业收入为0.00美元，每股基本收益为-2.80美元。从资产负债表来看，Inhibrx Biosciences, Inc.（INBX.US）总负债1.48亿美元，其中短期债务1.97百万美元，资产负债比为1.65，流动比率为0.06。机构评级：截至2025年5月23日，当前有1家机构对Inhibrx Biosciences, Inc.目标价做出预测，其中目标均价为12.00美元，其中最低目标价为12.00美元，最高目标价为12.00美元。公司简介：Inhibrx Biosciences Inc是一家临床阶段的生物制药公司，利用其专有的模块化蛋白质工程平台开发了一系列新型生物治疗候选药物。其临床治疗候选药物包括INBRX-109和INBRX-106，这两种药物均采用多价形式，可以以靶向为中心的方式优化精确的价态，以调节专家认为是主要的激动剂功能。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2537232369","isCrawlerRequest":true}